About Addex Therapeutics
Addex Therapeutics is a publicly listed company based in Geneve (Switzerland) founded in 2002. Oral small molecules for neurological disorders are developed. Addex Therapeutics has raised $71 million across 12 funding rounds from investors including Roche, Indivior and NIH. The company has 2 employees. Its chief executive, as recorded, is Tim Dyer. Addex Therapeutics offers products and services including Dipraglurant, ADX71149, and GABAB PAM. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is Addex Therapeutics Ltd.
Company details
Developer of oral small molecules for neurological disorders. The proprietary platform screens and identifies allosteric modulators. The product pipeline includes Diplaglurant for Parkinsons disease, specifically for Levodopa-induced Dyskinesia (PD-LID), ADX71149 for epilepsy, mGlu2 Nam for neurocognitive disorders, mGlu3 PAM Parkinsons disease, mGlu4 PAM for neurodegenerative disorders.
- Headquarters Geneve, Switzerland
- Employees 2
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website addextherapeutics.com
- Social LinkedIn X
- Legal Name Addex Therapeutics Ltd
- Annual Revenue$218.07 K (USD)-57.84as on Dec 31, 2025
- Net Profit-$8.49 M (USD)-195.36as on Dec 31, 2025
- EBITDA-$3.54 M (USD)-12.47as on Dec 31, 2025
- Total Equity Funding$71M (USD)
in 12 rounds
- Latest Funding Round$4.27M (USD), Grant
Sep 2023
- InvestorsRoche
& 22 more
- Employee Count2
Products & Services of Addex Therapeutics
Addex Therapeutics offers a comprehensive portfolio of products and services, including Dipraglurant, ADX71149, and GABAB PAM.
Targets post-stroke and TBI recovery as an mGlu5 NAM.
mGlu2 PAM for substance use disorder and epilepsy treatment.
Addresses chronic cough and substance use disorders.
Funding Insights of Addex Therapeutics
Addex Therapeutics has successfully raised a total of $71M across 12 strategic funding rounds. The most recent funding activity was a Grant round of $4.27 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $71M
- Total Rounds 12
- Last Round Grant — $4.27M
- First Round $39M
(May 2004)
- Investors Count 23
Latest 10 of 12 funding rounds of Addex Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $4.27M | Grant | – | – | – |
| Jul 2022 | $4.23M | Post-IPO | – | – | |
| Nov 2020 | $2.8M | Post-IPO | – | – | |
| Aug 2020 | Grant | – | – | ||
| Oct 2019 | $800,000 | Post-IPO | – | – | |
| Jul 2019 | Grant | – | – | – | |
| Sep 2018 | $1.58M | Grant | – | – | |
| Mar 2018 | $43M | Post-IPO | – | – | |
| Oct 2017 | $5.3M | Grant | – | – | |
| Jun 2017 | $2.98M | Post-IPO | – | – |
23 investors in total: 23 institutional.
Investors in Addex Therapeutics
Addex Therapeutics has secured backing from 23 investors, including institutional and venture fund investors. Prominent investors backing the company include Roche, Indivior and NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Venture capital investments in technology startups and entrepreneurs. | indexventures.com | |||
Capital is invested in life science innovations for healthcare transformation. | tvm-capital.com | Munich, Germany | ||
VARUMA AG is based in Basel, Switzerland. | varuma.ch | Basel, Switzerland | ||
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Stage-agnostic investments are directed toward European startups in key sectors. | polytechnos.com | Munich, Germany | ||
| bio1capital.com | ||||
Life Sciences sector focused early stage VC firm investing primarily in Europe | sofinnova.fr | Paris, France |
Investor details for Addex Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Addex Therapeutics
19 people are tracked at Addex Therapeutics (7 in leadership, 7 in board & advisors, 5 in team); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
Tim Dyer | CEO | Leadership |
Christelle Bolea | Laboratory Head/Project Leader | Leadership |
Mikhail Kalinichev | Head of Translational Science | Leadership |
Eric Gaillard | Head of IT & Facility | Leadership |
Stuart Rigby | Head Of Project Management Office | Leadership |
Raedeit Kifle | Executive Assistant to CEO | Leadership |
Lénaic Teyssédou | Head of Finance - Principal accounting officer | Leadership |
Bernard Bettler | Board Member | Board & advisors |
Vincent Lawton | Chairman, Board of Directors | Board & advisors |
Jake Nunn | Director | Board & advisors |
Mark F. Bear | Board Member | Board & advisors |
Ray Hill | Director | Board & advisors |
Darryle D Schoepp | Chairman, Scientific Advisory Board | Board & advisors |
Isaac Manke | Director | Board & advisors |
Roger Mills | Member Board Of Directors | Team |
Alexie Javault | Research Assistant | Team |
Tea Kullamaa | Senior Accountant | Team |
Arnaud Besson | Research Associate and Compound Manager | Team |
cécile ferry | research scientist | Team |
Complete people profiles for Addex Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Addex Therapeutics
Addex Therapeutics is a publicly listed company on the SIX with ticker symbol ADXN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Jan 2020
- Listed onNASDAQ: ADXN
- Listed entityAddex Therapeutics Ltd
- Exchange sectorHealth technology
- ISINCH0029850754
- Share price0.05 CHF (+1.27% on the day) · 2026-05-11
- Market capitalisation5,566,160.00 CHF
- EPS (diluted, trailing year)-0.06 CHF
- Volume (last session)30,340
- Analyst consensusNo rating
Financials of Addex Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 172,860 CHF | -6.7M CHF | -2.8M CHF |
| 2024 | 410,040 CHF | 7.1M CHF | -2.5M CHF |
| 2023 | 1.6M CHF | -10.6M CHF | -1.9M CHF |
| 2022 | 1.4M CHF | -20.8M CHF | -20.2M CHF |
| 2021 | 2.9M CHF | -15.3M CHF | -15.4M CHF |
Detailed financial statements for Addex Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Addex Therapeutics
4 dated milestones of Addex Therapeutics across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Addex Therapeutics is founded.
- Funding First funding round of $39.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $4.3M.
Web traffic of Addex Therapeutics
The website of Addex Therapeutics (addextherapeutics.com) receives about 3.3K visits a month and ranks #7,605,013 among all websites worldwide, #7,083 in Biotechnology and Pharmaceuticals.
- Monthly visits3.3K
▲ 40.2% vs previous month
- Global rank#7,605,013
among all websites
- Category rank#7,083
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.4
- Average visit6 sec
- DevicesDesktop 32% · Mobile 68%
Websites whose visitors overlap most with Addex Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| taurx.com | 100% | 8.1K | #2,623,902 | View details | |
| adamaspharma.com | 99% | View details | |||
| auspexpharma.com | 99% | View details | |||
samaritanpharma.com | samaritanpharma.com | 98% | – | ||
sincerpharmchem.com | sincerpharmchem.com | 98% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Addex Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Addex Therapeutics
Complete news archive for Addex Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Addex Therapeutics
Addex Therapeutics was founded in 2002 and raised its 1st funding round 2 years after it was founded.
Addex Therapeutics is headquartered in Geneve, Switzerland. It is registered at Geneve, Geneve, Switzerland.
Tim Dyer is the CEO of Addex Therapeutics, as recorded in our data.
Addex Therapeutics is a funded company, having raised a total of $71M across 12 funding rounds to date. The company's 1st funding round was a Post-IPO of $2.98M, raised on May 2004.
Addex Therapeutics has 2 employees.
Annual revenue of Addex Therapeutics is $218.07K as on Dec 31, 2025.
Developer of oral small molecules for neurological disorders. The proprietary platform screens and identifies allosteric modulators. The product pipeline includes Diplaglurant for Parkinsons disease, specifically for Levodopa-induced Dyskinesia (PD-LID), ADX71149 for epilepsy, mGlu2 Nam for neurocognitive disorders, mGlu3 PAM Parkinsons disease, mGlu4 PAM for neurodegenerative disorders.
Addex Therapeutics offers Dipraglurant, ADX71149, and GABAB PAM.
Yes, Addex Therapeutics is publicly traded on SIX under the ticker symbol ADXN.
Addex Therapeutics has 23 investors. Key investors include Roche, Indivior, NIH, New Leaf Venture Partners, and Fulcrum Pharma Developments.
Addex Therapeutics operates through Addex Therapeutics Ltd.